Skip to main content
. 2024 Jul 1;8:139. doi: 10.1038/s41698-024-00625-7

Fig. 4. BCL6 inhibits T-cell infiltration and activation.

Fig. 4

a tSNE distribution of immune cells after dimensional reduction for CyTOF of H22 WT and Bcl6 KO tumors. b CD45+immune cells and CD45+CD3+T cells quantification using FACS for H22 tumors and Hepa1-6 tumors, n = 4–6 per group. c Immunohistochemistry showed more infiltration of T cells in H22 Bcl6 KO-derived tumor compared to WT, scale: 50 μm. d FACS quantification of Th1, Th2, Th17 and Treg for H22 WT and Bcl6 KO tumors, n = 4 per group. e FACS quantification of Th1, Th2, Th17 and Treg for Hepa1-6 vector (Ctrl) and Bcl6 overexpression (Bcl6) tumors, n = 4 per group. f FACS quantification of IfnR+Tnfa+CD8+T cells and Granzyme B+CD8+T cells infiltration in H22 derived liver tumors and Hepa1-6 derived tumors, n = 4 per group. g Flow cytometry quantification of CD4+and CD8+T cells proliferation, n = 4 per group. FACS quantification shown the CD45+immune cells (h), CD45+CD3+T cells (i), Th1 (j), Th2 (k) and Th17 (l) infiltration kinetics in H22 WT and Bcl6 KO liver tumors, n = 3–4 per group each time point, *: Bcl6 KO#1 compared to WT, #: Bcl6 KO#2 compared to WT. *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.05, ##p < 0.01, ns: not significant.